Kestra Medical Technologies, Inc.

Biopharma financing during the first quarter of 2025 totaled $13.1bn from 206 deals. The venture financing category made up the greatest proportion of both the aggregate Q1 financing dollars (46%) and

Biopharma financing during the third quarter of 2024 totaled $17bn from 207 deals. Of those, 54 reached $100m or more. The follow-on public offering (FOPO) category made up the made up most (34%) of t